A similar trend was also observed in Subramanian et al.’s [142] study, which employed the Hsp90 inhibitor to reduce both CD44 and ALDH subpopulations in vitro and reduced tumor volume in vivo, which were resistant to cisplatin treatment. Here, CD44 is linked to neoplasm.